There is no single LDL cholesterol number that suits everyone. Trials have not found a level below which lowering LDL stops reducing heart attacks and strokes, so guidelines set lower goals for people at higher risk.
For people with established artery disease at very high risk, current US and European guidance both point to an LDL below 55 mg/dL. Very low levels have looked safe in trials lasting several years. Evidence over decades is thinner, and that limit deserves to be stated plainly.
Key takeaways
- Genetic studies, cohort studies and drug trials all point the same way: lower LDL over a longer time means less artery disease.
- Pooled statin trials found no LDL threshold where the benefit stopped within the range they studied.
- Your goal depends on your risk category, and the strictest goals are for people who already have artery disease.
- Trials that drove LDL to around 30 mg/dL did not find more side effects over follow-up of up to about eight years.
- How low to aim, and with what, is a decision for you and your prescriber.
Why "lower is better" became the working rule
LDL particles carry cholesterol into the artery wall, where plaque forms. The question is whether reducing them reduces disease in step, or only up to a point.
A European Atherosclerosis Society consensus panel reviewed more than 200 studies covering over 2 million participants and found a consistent, dose-dependent relationship between exposure to LDL cholesterol and the risk of atherosclerotic cardiovascular disease.1 The effect grew with the length of exposure. In other words, both how high and how long matter.
Statin trials tested the idea directly. A pooled analysis of 26 trials found similar proportional reductions in major vascular events for each 1.0 mmol/L (about 39 mg/dL) of LDL lowering in every type of patient studied, including people whose LDL was already below about 77 mg/dL. The authors saw no evidence of a threshold within the range studied.2
What happened when trials pushed LDL lower
Newer medicines added to statins made it possible to test lower LDL levels than statins alone usually reach.
One trial added a second pill to a statin and brought average LDL from about 70 to about 54 mg/dL, with fewer cardiovascular events. Another added an injectable PCSK9 antibody and reached a median of 30 mg/dL, again with fewer events. Both are described in our guide to non-statin medicines.
A planned analysis of the second trial, FOURIER, sorted nearly 26,000 participants by the LDL level they reached. Risk kept falling as LDL fell, down to levels below 0.2 mmol/L, which is about 8 mg/dL.3 One in ten participants reached an LDL under about 19 mg/dL.
These trials enrolled people who already had artery disease. They show that lower LDL helped that group. They do not show that everyone should aim that low.
What guidelines set as goals
For some years US and European guidance used different language. The 2018 US guideline used a treatment threshold, an LDL of 70 mg/dL or higher, as the point for considering added therapy in the highest-risk patients, while European guidance set a goal of under 55 mg/dL for the same kind of patient.4
The 2026 ACC/AHA guideline, which replaced the 2018 document, brought numeric goals back.
| Source | Who | LDL cholesterol position |
|---|---|---|
| 2018 US guideline (now retired) | Highest-risk patients with artery disease | Threshold of 70 mg/dL or higher to consider adding therapy |
| European (ESC/EAS) guidance | Very high risk, such as after a heart attack | Goal below 55 mg/dL |
| 2026 ACC/AHA guideline | Clinical artery disease at very high risk | Goal below 55 mg/dL, with non-HDL cholesterol below 85 mg/dL |
In people with clinical artery disease at very high risk, the 2026 guideline recommends LDL cholesterol below 55 mg/dL and non-HDL cholesterol below 85 mg/dL.5 It also sets goals for people without known disease, graded by risk category. Those are laid out in LDL cholesterol levels by risk.
The 2026 guideline also names goals for non-HDL cholesterol and, in select cases, ApoB. See the ApoB levels chart for why some clinicians track ApoB alongside LDL.
Is very low LDL safe?
This is the question most people ask next, and trials have looked for harm directly.
In the FOURIER analysis, there was no significant association between the LDL level reached and serious adverse events or any of the other safety outcomes examined, over a median of 2.2 years. That included the people with the very lowest levels.
A longer follow-up enrolled 6,635 FOURIER participants, with a median of five more years and a maximum of 8.4 years on the medicine. About 63% reached an LDL below 40 mg/dL. Rates of serious adverse events, muscle-related events, new diabetes, bleeding stroke and neurocognitive events did not exceed those seen with placebo in the original trial and did not rise over time.6
The pooled statin trials found no significant effect on cancer rates, even at low LDL levels.
What is not known:
- Decades. The longest of these data run to about eight years, not twenty or thirty.
- Other groups. Participants had established disease and were selected for trials. Younger, lower-risk adults were not studied this way.
Why the lowest number is not automatically the right goal
A lower LDL reduces risk in proportion to the drop. How much that is worth depends on how much risk you had to begin with. For someone at very high risk, a further drop can prevent a meaningful number of events. For someone at low risk, the same drop prevents few.
Getting lower may also mean a higher-intensity statin or a second medicine, with the cost and side effects that come with it. Guidelines treat this as a shared decision for that reason.
Do not begin, stop or adjust any cholesterol medication to chase a number without talking with your prescriber first.
Next step: find out where you stand
A goal only helps if you know your starting point and your risk category. Both Cardio Res-Q assessments, the Comprehensive Assessment ($775) and the Enhanced Assessment ($999), measure ApoB and Lp(a) and include a clinical evaluation. The Enhanced Assessment adds a calcium score and a CIMT ultrasound.
See the Cardio Res-Q program page for what is included. If you are already on treatment, read Already on a Statin? first. The clinic can share your results with your prescriber.
Are You a Candidate for Cardio Res-Q?
Three quick questions about the risk factors we screen for. Your answers stay between you and the clinic.
Frequently asked questions
Can LDL cholesterol be too low?
Trials have not found a level where harm appears. In studies that brought LDL to around 30 mg/dL and lower, side effects were no more common than with placebo over follow-up of up to about eight years. Longer-term data are limited, so this is still watched.
What LDL should I aim for?
It depends on your risk category. The 2026 US guideline recommends below 55 mg/dL for people with artery disease at very high risk and sets other goals for other groups. Your clinician can tell you which category you are in.
My LDL is under 100. Is that good enough?
It may be, or it may not, depending on your risk. A level that is fine for a low-risk adult is above goal for someone who has had a heart attack. LDL also misses some of the picture, which is why ApoB and Lp(a) are worth knowing.
Related reading
This article is for general education and is not medical advice. Decisions about testing and medication should be made with your clinician. If you have chest pain or other symptoms of a heart attack, call 911.
